Investors Alert: Class Action Lawsuit Filed Against Tenax Therapeutics in NASDAQ

Investors on Alert: Class Action Lawsuit Against Tenax Therapeutics

A significant legal development has emerged in the pharmaceutical industry as Berger Montague, a well-known plaintiffs' law firm, has initiated a class action lawsuit against Tenax Therapeutics, Inc. (NASDAQ: TENX). This legal action is aimed at protecting the rights of investors who acquired Tenax securities between November 13, 2023, and August 7, 2026, part of what is referred to as the Class Period. As the situation unfolds, interested investors are encouraged to understand the implications surrounding this lawsuit.

Background of the Case

The lawsuit was filed in the United States District Court for the Middle District of North Carolina, under case number 26-cv-01624. It centers on allegations of misleading statements made by Tenax and its executives about the prospects of its leading drug candidate, TNX-103. This oral medication was purportedly developed for treating pulmonary hypertension, particularly in patients with heart failure who display preserved ejection fraction (PH-HFpEF).

During the Class Period, Tenax's management co-opted a positive narrative about TNX-103, suggesting that its development was secure and promising. They emphasized that the existing approval for similar conditions and appealing results from the Phase 2 HELP study lent credibility to their claims. However, the lawsuit argues that significant information was concealed from investors, specifically that TNX-103 might not perform as effectively as presented. In addition, it alleges that the clinical, regulatory, and commercial possibilities of TNX-103 were largely exaggerated.

Allegations of Misconduct

The core of the allegations rests on violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5. According to the complaint, on August 10, 2026, Tenax disclosed results from the Phase 3 LEVEL trial, reporting that TNX-103 failed to achieve its main goal of improving the distance walked in six minutes compared to a placebo. Furthermore, it did not meet its secondary endpoint related to improving symptoms as gauged by the Kansas City Cardiomyopathy Questionnaire.

This profound disappointing announcement led to drastic consequences for Tenax's stock price, which plummeted approximately 89.77%, closing at around $1.38 per share on that day. This significant loss profoundly affected investors and served as a catalyst for the ensuing legal actions.

Call to Investors

For investors who purchased Tenax securities within the class period, the deadline to apply to be a lead plaintiff is December 28, 2026. This is an opportunity for investors to potentially recover losses incurred due to the alleged misrepresentations made by Tenax and its executives. The lawsuit reflects the broader responsibilities companies have toward their investors, particularly regarding transparency and honesty about the efficacy of their products.

Investors seeking further information about their rights in this matter may reach out to Berger Montague. Points of contact include Andrew Abramowitz at [email protected] and Caitlin Adorni at [email protected] The firm is recognized for its role in complex litigation and has historically secured substantial recoveries for plaintiffs, with a track record that exceeds $50 billion.

About Tenax Therapeutics

Tenax Therapeutics is based in Chapel Hill, North Carolina, focusing on developing advanced therapies for cardiopulmonary conditions. While TNX-103 is its prioritized product, the company is in a development stage and remains to be scrutinized amid these legal challenges.

Conclusion

As the class action lawsuit unfolds, it represents not only a significant event for Tenax Therapeutics but also a critical case study for investors reflecting on their rights concerning corporate disclosures. Berger Montague and similar firms play a vital role in holding companies accountable while offering a pathway for investors to assert their claims in the face of perceived injustices.